BioSpace News Archive

Aethlon Medical, Inc., a therapeutic medical device company focused on addressing critical unmet needs in global health, announces the appointment of Lisa M. Boswell, to the position of Director, Quality Systems and Regulatory Affairs.

The Phase 3 CLL14 trial of venetoclax in combination with obinutuzumab is the first randomized clinical trial to examine a chemotherapy-free treatment given for a fixed duration in previously-untreated patients with chronic lymphocytic leukemia (CLL) and comorbidities

Secured the potential for up to $5 million in new funding ($1.5 million of which has been funded to date) and further secured a 9% royalty on future U.S. sales of SUBA®-Itraconazole for basal cell carcinoma nevus syndrome (BCCNS) through revised agreement with majority shareholder and licensor Mayne Pharma Ventures Pty Ltd. (Mayne Pharma) Secured exclusive option to license next-generation itraconazole analogues from University of Connecticut (UCONN) for potential pipeline expansion, a

PDL BioPharma, Inc. announced that it will release its 2018 fourth quarter and full year financial results for the period ended December 31, 2018, on Thursday, March 14, 2019, after market close.

Abid Nazeer, MD, Chief Medical Officer of Symetria Health, unveils redefined treatment strategies in wake of deadly fentanyl emergence at Midwest Opioid Summit

Worldwide Clinical Trials, Inc., an award-winning, full-service, midsize, global CRO, and Deep Lens, an AI-driven digital pathology company focused on disease diagnosis confirmation and clinical trial recruitment, announced a new strategic alliance in oncology.

Home infusion therapy providers and HME pharmacies benefit from feature-rich functionality within a single software solution for all clinical, billing and reporting needs

Accreditation Council for Medical Affairs and Dynamic Global Events are excited to announce a partnership to bring the first ever CE accredited live events for pharmaceutical industry professionals.

Advanced Analytics and Personalized Itinerary Enables Health Systems to Acquire, Activate and Retain Patients

Retirement of existing term loan will strengthen near-term cash flows and extend cash runway past an anticipated NDA filing in the second half of 2020